DexCom Inc (DXCM)vsLucid Diagnostics Inc (LUCD)
DXCM
DexCom Inc
$85.06
-1.00%
HEALTHCARE · Cap: $32.21B
LUCD
Lucid Diagnostics Inc
$0.54
-10.38%
HEALTHCARE · Cap: $121.83M
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 91162% more annual revenue ($4.97B vs $5.45M). DXCM leads profitability with a 20.1% profit margin vs 0.0%. DXCM earns a higher WallStSmart Score of 74/100 (B).
DXCM
Strong Buy74
out of 100
Grade: B
LUCD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+90.0%
Fair Value
$678.36
Current Price
$85.06
$593.30 discount
Intrinsic value data unavailable for LUCD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Revenue surging 26.7% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Trading at 12.2x book value
Trading at 9.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bull Case : LUCD
The strongest argument for LUCD centers on Revenue Growth. Revenue growth of 26.7% demonstrates continued momentum.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : LUCD
The primary concerns for LUCD are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.28 is elevated, increasing financial risk.
Key Dynamics to Monitor
DXCM profiles as a mature stock while LUCD is a growth play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.42 — expect wider price swings.
LUCD is growing revenue faster at 26.7% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 24/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Lucid Diagnostics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Lucid Diagnostics Inc. is a commercial stage medical diagnostic technology company. The company is headquartered in New York, New York.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?